Media banner

Video &  Social Media

Watch us in interviews. Follow us.


  • No effective treatment exists for the estimated 250,000 children born worldwide each year with pediatric minimally verbal autism (PMVA), of those approximately 20,000 are born in the U.S.

  • Orphan Drug designation application to be filed in June 2019 based on Q BioMed's recent breakthrough discovery of disease biomarkers

  • Short 12 month pivotal clinical trial to start as early as Q1 2020

New York, New York--(Newsfile Corp. - June 4, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today announced advancements on several fronts for its key asset, QBM-001, in the treatment of pediatric minimally verbal autism (PMVA), a rare autism spectrum disorder (ASD) for which no effective treatment currently exists. Globally, over 250,000 children are born with PMVA per year, 20,000 of them the U.S.

"Children affected by pediatric minimally verbal autism are in dire need of an effective treatment," stated Q BioMed CEO Denis Corin. "Q BioMed is committed to delivering relief to the children and families that are impacted by this condition. The emotional strain of never talking with one's child can be severe, and the direct financial costs over a lifetime are estimated to be $4.5 million per family."

"We are proud of the scientific breakthrough we've made to date, with the discovery of the RNA biomarkers correlated with PMVA. This new data has accelerated QBM-001 towards clinical development. The data improves our clinical trial design, provides valuable insight for regulators, and opens doors with new collaborators and Key Opinion Leaders in the field," noted Corin.

Recent achievements and upcoming milestones in QBM-001's path to market include:

  • Discovery of Biomarkers in April 2019

    In April, Q BioMed announced its discovery of the first biomarkers to identify PMVA. The company's study examined 1,953 autistic biomarkers, resulting in two significant markers tied to expressed genes and pathways responsible for speech development. These biomarkers will help identify and homogenize clinical trial participants, and will be studied as possible diagnostic and prognostic indicators during trials. Successful outcomes would allow for a diagnosis as young as 18 months.
  • Attendance and Enthusiastic Reception at the International Society for Autism Research (INSAR) Annual Meeting in 2019

    Q BioMed attended the largest clinical and research focused conference for autism, the International Society for Autism Research Annual Meeting, in May. The independent findings at the conference provided unique insight into PMVA and also confirmed that PMVA can be stratified as a subset from other ASDs. These INSAR findings, along with Q BioMed's biomarker study, allowed the company to organize an advisory board meeting at INSAR to prepare regulatory and diagnostic guidelines for PVMA. Q BioMed is currently in discussions with clinics and research centers from the conference regarding potential partnerships and collaborations.
  • Orphan Drug Application in June 2019

    Q BioMed plans to apply for Orphan Drug designation for QBM-001 with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in June. Orphan designation can be given to drugs that treat indications impacting less than 200,000 patients per year in the U.S. Of the estimated 67,000 children diagnosed with autism spectrum disorder each year in the U.S., 20,000 become minimally-verbal; QBM-001 should be able to treat 15,000 of these children. Orphan Drug designation offers clinical development benefits including tax credits and eligibility for seven years of market exclusivity in the U.S. and 10 years in Europe.
  • Biomarker Validation Study Completion in Q4 2019

    Currently, Q BioMed is working on finalizing its biomarker validation study with its partners, and anticipates completion of this study during the fourth quarter of 2019.
  • Initiate Clinical Trial in Q1 2020

    QBM-001 has completed its first phase of formulation work; the second phase of formulation is expected to be finalized in August 2019. At that time, Q BioMed will request a pre-Investigational New Drug (IND) meeting with the U.S. FDA, and similar discussions with Europe's EMA. Based on regulatory guidance, Q BioMed anticipates filing its IND submissions, including its current clinical trial design which is planned and ready to propose, by December of this year. Clinical trials may commence as early as Q1 2020.
  • Collaborators and Key Opinion Leaders in Coming Quarters

    Following the discovery of biomarkers, Q BioMed has received keen interest from potential collaboration partners and thought leaders in autism. Q BioMed plans to add additional Key Opinion Leaders in autism and PMVA to its Advisory Board in the coming quarters.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit and sign up for regular updates.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Denis Corin
Q BioMed Inc.

Investor Relations
+1(404) 995-6671
This email address is being protected from spambots. You need JavaScript enabled to view it.

To view the source version of this press release, please visit